Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Tommy A BrownKevin ByrdTimothy J VreelandG Travis CliftonDoreen O JacksonDiane F HaleGarth S HerbertJohn W MyersJulia M GreeneJohn S BerryJonathan MartinJohn C ElkasThomas P ConradsKathleen M DarcyChad A HamiltonGeorge L MaxwelGeorge E PeoplesPublished in: Cancer medicine (2019)
This phase I/IIa trial reveals that E39 + GM-CSF is safe and may be effective in preventing recurrence in high-risk ovarian and endometrial cancer when optimally dosed (1000 μg) to FBP low patients being treated for primary disease.